Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

402
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
402
Drug Discovery: Overview01:26

Drug Discovery: Overview

7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

176
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
176
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

147
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
147

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness analysis of resective epilepsy surgery in drug-resistant patients: an artificial intelligence data modeling.

Epilepsy & behavior : E&B·2026
Same author

Reduced CD40 expression in B cell subsets of individuals with radiologically isolated syndrome.

Frontiers in immunology·2025
Same author

Lessons Learned: Quality Analysis of Optical Coherence Tomography in Neuromyelitis Optica.

Annals of clinical and translational neurology·2025
Same author

Multiscale networks in Alzheimer's disease identify brain hypometabolism as central across biological scales.

PLoS computational biology·2025
Same author

The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2025
Same author

Diffusivity anisotropy signature of slowly expanding lesions predicts progression independent of relapse activity in multiple sclerosis.

Journal of neurology, neurosurgery, and psychiatry·2025

Related Experiment Video

Updated: May 25, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.1K

Ongoing phase 2 agents for multiple sclerosis: could we break the phase 3 trial deadlock?

Silvia Susin-Calle1, Jose Enrique Martinez-Rodriguez1, Elvira Munteis1

  • 1Department of Neurology, Hospital del Mar Research Institute and Pompeu Fabra University, Barcelona, Spain.

Expert Opinion on Investigational Drugs
|February 25, 2025
PubMed
Summary

Investigating new treatments for multiple sclerosis (MS) shows promise in phase 2 trials. However, challenges remain in translating these findings to phase 3 trials for progressive MS, requiring better biomarkers and trial designs.

Keywords:
Multiple sclerosisclinical trialsdisease modifying therapiesneurodegenerationneuroimmunologynew therapiesphase 2phase 3

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.4K
Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.0K

Related Experiment Videos

Last Updated: May 25, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.1K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.4K
Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability
08:22

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

8.0K

Area of Science:

  • Neurology
  • Clinical Trials
  • Neuroimmunology

Background:

  • Multiple sclerosis (MS) is a chronic central nervous system disease with inflammatory and neurodegenerative components.
  • Current disease-modifying therapies are effective for relapsing MS, but progressive MS presents a significant clinical challenge.
  • There is a critical need for novel therapeutic strategies targeting both inflammation and neurodegeneration in MS.

Purpose of the Study:

  • To review recent and ongoing phase 2 clinical trials for multiple sclerosis treatments.
  • To categorize trials based on therapeutic goals: immunomodulation, neuroprotection, and remyelination.
  • To highlight promising therapies addressing the dual pathology of MS.

Main Methods:

  • Comprehensive literature search of PubMed and ClinicalTrials.gov.
  • Identification of phase 2 clinical trials for multiple sclerosis.
  • Categorization of trials by therapeutic approach (immunomodulatory, neuroprotective, remyelinating).

Main Results:

  • Phase 2 trials are exploring diverse therapeutic avenues for MS.
  • Emerging results from these trials offer insights into potential future treatments.
  • A focus on therapies targeting both inflammatory and neurodegenerative aspects of MS is evident.

Conclusions:

  • Translating phase 2 successes to phase 3 trials for MS is hindered by biomarker limitations and trial design issues.
  • Refining biomarkers, standardizing outcome definitions (e.g., PIRA), and improving trial designs are crucial for advancing MS therapeutics.
  • Addressing the complexities of progressive MS requires innovative approaches in clinical trial methodology.